Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H29N2O |
| Molecular Weight | 337.4785 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
C[N+]3(CCC(C(N)=O)(C1=CC=CC=C1)C2=CC=CC=C2)CCCCC3
InChI
InChIKey=QDIYJDPBMZUZEH-UHFFFAOYSA-O
InChI=1S/C22H28N2O/c1-24(16-9-4-10-17-24)18-15-22(21(23)25,19-11-5-2-6-12-19)20-13-7-3-8-14-20/h2-3,5-8,11-14H,4,9-10,15-18H2,1H3,(H-,23,25)/p+1
| Molecular Formula | C22H29N2O |
| Molecular Weight | 337.4785 |
| Charge | 1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Fenpiverinium is a quaternary ammonium compound, it is an anticholinergic and antispasmodic agent. It is a constituent of Baralgin. The effects of the constituents of Baralgin (metamizole , fenpiverinium, and pitofenone ) on mechanical activity were studied in isolated human preparations of the upper urinary tract. Fenpiverinium blocked the increase in frequency of phasic-rhythmic contractions and the tonic tension development induced by acetylcholine. Fenpiverinium did influence neither spontaneous phasic activity nor activation by high potassium or norepinephrine. Fenpiverinium has exclusively anticholinergic properties. Fenpiverinium is a muscarinic acetylcholine receptor antagonist.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094109 Sources: https://www.genome.jp/dbget-bin/www_bget?dr:D07070 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Open labelled evaluation of injection Manyana (a combination of diclofenac + pitofenone + fenpiverinium) in ureteric, biliary and intestinal spasm--a preliminary report. | 1999-09 |
|
| Analgesics for pain relief after gynaecological surgery. A two-phase study. | 1985-03-02 |
|
| [Effect of Baralgin on isolated preparations of the upper urinary tract in man]. | 1984 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3885441
A two-phase, double-blind study was performed to assess the efficacy of various drugs in the relief of postoperative pain. Oral analgesia with two compounds (paracetamol 320 mg, caffeine 32 mg, codeine phosphate 8 mg and meprobamate 150 mg (Stopayne; Rio Ethicals) and dipyrone 500 mg, pitofenone hydrochloride 5 mg and fenpiverinium bromide 0,1 mg (Baralgan HS; Albert)) was found to produce satisfactory pain relief, and it is suggested that these oral compounds may be used from 12 hours postoperatively in uncomplicated cases.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:44:53 GMT 2025
by
admin
on
Mon Mar 31 18:44:53 GMT 2025
|
| Record UNII |
KP2L8LC73B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
||
|
WHO-ATC |
A03AB21
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
||
|
WHO-VATC |
QA03AB21
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C87638
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
1160
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
258329-46-3
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
FENPIVERINIUM
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
DB13759
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
C005711
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
71490
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
SUB02124MIG
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
100000086984
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
KP2L8LC73B
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
DTXSID7048376
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |